Daily Courier: Single Column

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

136.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,225
Open 136.36
Bid (Size) 136.50 (200)
Ask (Size) 137.20 (300)
Prev. Close 136.36
Today's Range 136.36 - 136.36
52wk Range 107.75 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.41%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stay informed with the top movers within the S&P500 index on Tuesday. ↗
Via Chartmill
News headline image
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says ↗
HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential. 
Via Benzinga

Performance

YTD
+12.1%
+12.1%
1 Month
+6.4%
+6.4%
3 Month
-1.8%
-1.8%
6 Month
+12.4%
+12.4%
1 Year
+22.0%
+22.0%

More News

Read More
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
Via Investor Brand Network
News headline image
FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? ↗
Via The Motley Fool
Topics ETFs
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector ↗
Via Chartmill
News headline image
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗
Via Benzinga
News headline image
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns ↗
Via The Motley Fool
Topics ETFs
News headline image
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer ↗
Via Benzinga
News headline image
This ETF Has More Than Doubled the S&P 500's Returns Over the Past Decade. Is It a Buy for the Next Decade? ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
Via MarketBeat
Topics ETFs
News headline image
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 S&P 500 Stocks with Exciting Potential
Via StockStory
Topics Stocks
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?
Via StockStory
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
Via Benzinga
News headline image
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off
Via StockStory
News headline image
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
From Gilead Sciences, Inc.
Via Business Wire
News headline image
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial ↗
Via Benzinga
News headline image
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
From Merck & Co., Inc.
Via Business Wire

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 136.36
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 07/07/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 170.97B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 171B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

© Copyright 2015, Daily Courier, Kelowna, BC. Powered by BLOX Content Management System from TownNews.com.